0/100 · Low Risk
Manufactured by Boiron
No Adverse Events Reported for Golden Seal
Last updated: 2026-05-12
GOLDENSEAL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Boiron. Based on analysis of FDA adverse event reports, GOLDENSEAL has a safety score of 0 out of 100. This lower score reflects a significant number of adverse event reports, suggesting that patients should discuss potential risks carefully with their healthcare provider. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GOLDENSEAL.
Goldenseal has a safety concern score of 0 out of 100, placing it in the low concern category based on analysis of FDA adverse event data. The FDA has received approximately N/A adverse event reports for this medication, which is primarily manufactured by Boiron.
No serious or non-serious adverse events reported for Golden Seal.
The drug has been reported by a small number of individuals, with no clear patterns observed. The age distribution of reported users is diverse, ranging from 26 to 84 years old.
Patients taking Goldenseal should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Goldenseal received a safety concern score of 0/100 (low concern). The score accounts for N/A total adverse event reports and 0 distinct reaction types. This relatively low score suggests a favorable safety profile in reported data.
The most frequently reported age groups are age 36 (2 reports), age 61 (2 reports), age 65 (2 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
If you are taking Goldenseal, here are important things to know. No specific precautions or warnings are necessary based on the current data. Continue to monitor for any new adverse events as more data becomes available. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA has received approximately N/A adverse event reports associated with Goldenseal. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported age groups for Goldenseal adverse events are: age 36: 2 reports, age 61: 2 reports, age 65: 2 reports, age 71: 2 reports, age 26: 1 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Goldenseal adverse event reports is Boiron. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
You can report adverse events from Goldenseal to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Goldenseal has a safety concern score of 0 out of 100 (low concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. No serious or non-serious adverse events reported for Golden Seal.
Key safety signals identified in Goldenseal's adverse event data include: No serious adverse events reported.. No non-serious adverse events reported.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
No specific precautions or warnings are necessary based on the current data. Continue to monitor for any new adverse events as more data becomes available.
Goldenseal has N/A adverse event reports on file with the FDA. The drug has been reported by a small number of individuals, with no clear patterns observed. The volume of reports for Goldenseal reflects both the drug's usage level and the vigilance of the reporting community.
Explore other medications manufactured by Boiron and compare their safety profiles:
Drugs related to GOLDENSEAL based on therapeutic use, drug class, or shared indications: